TARA

Protara Therapeutics, Inc.

Healthcare
Biotechnology
$215M market cap

Forecast run · Sep 14, 2026Upside rank 1440 of 3,136

Model Signal

ForecastQ Daily Probabilities

36.4%

42.9%

17.3%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$3.82

Price target$12.00

Implied move+214.1%

Analysts6

ForecastQ Portfolios

TARA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.